



## Myelodysplastic Syndromes (MDS): Enhancing Survival in Higher-Risk Patients

- Untreated patients with intermediate-2 or high-risk MDS (International Prognostic Scoring System [IPSS] criteria) have what survival expectancy?
  - 0.2 to 0.6 years
  - 0.4 to 1.1 years
  - 0.9 to 2.5 years
  - 1.5 to 5.6 years
- What proportion of intermediate-2 or higher-risk patients (IPSS criteria) with MDS are red blood cell (RBC) transfusion-dependent?
  - 33%
  - 54%
  - 68%
  - 92%
- What proportion of patients with MDS are suitable candidates for treatment with high-dose chemotherapy and allogeneic bone marrow transplantation?
  - 5%
  - 15%
  - 30%
  - 45%
- Fenaux et al compared azacitidine with best conventional care (including low-dose cytarabine and aggressive chemotherapy) in patients with higher-risk MDS. The median survival for the conventional care group was 15 months. What was the median survival for the azacitidine-treated group?
  - 14.2 months
  - 18.9 months
  - 24.5 months
  - 32.3 months
- A 76-year-old man has RBC transfusion-dependent MDS classified as intermediate-2 risk by IPSS criteria. Which initial treatment approach would you favor?
  - best supportive care only
  - high-dose chemotherapy with allogeneic marrow transplant
  - azacitidine
  - low-dose cytarabine

### Answer Sheet - Retain a copy for your records!

- A  B  C  D
- A  B  C  D
- A  B  C  D
- A  B  C  D
- A  B  C  D

Answers: 1. B 2. C 3. A 4. C 5. C

Please rate this CME exercise using the scale:  
A = inadequate, B = minimally adequate,  
C = satisfactory, D = very good, E = excellent.

Did the article in this issue meet the stated objectives?

- A  B  C  D  E

Was the information relevant to your practice in oncology?

- A  B  C  D  E

Were your educational needs met regarding these topics?

- A  B  C  D  E

Was the CME posttest scientifically rigorous?

- A  B  C  D  E

Please PRINT clearly:

Name: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_

State: \_\_\_\_\_ ZIP: \_\_\_\_\_

E-mail address: \_\_\_\_\_

Self-reported scoring — number correct: \_\_\_\_

Submit to:

**John M. York, PharmD**

**Akita Biomedical Consulting**

Fax: 949-203-6115

E-mail: johnyork@akitabiomedical.com